Circulating Inflammation Markers, Risk of Lung Cancer, and Utility for Risk Stratification.
about
Serum biomarkers of polyomavirus infection and risk of lung cancer in never smokersIncreased serum amyloid A as potential diagnostic marker for lung cancer: a meta-analysis based on nine studiesElevated expression of IFN-inducible CXCR3 ligands predicts poor prognosis in patients with non-metastatic clear-cell renal cell carcinoma.CXCL9: evidence and contradictions for its role in tumor progression.MDC and BLC are independently associated with the significant risk of early stage lung adenocarcinoma.Diagnostic and prognostic value of serum MACC1 in breast cancer patients.Associations between self-reported diabetes and 78 circulating markers of inflammation, immunity, and metabolism among adults in the United StatesCancer and inflammation.Sufficient dimension reduction for censored predictors.Identification of the prognostic value of lymphocyte-to-monocyte ratio in patients with HBV-associated advanced hepatocellular carcinoma.A cross-sectional study of changes in markers of immunological effects and lung health due to exposure to multi-walled carbon nanotubes.Impaired functional vitamin B6 status is associated with increased risk of lung cancer.Occupational exposure to diesel engine exhaust and alterations in immune/inflammatory markers: a cross-sectional molecular epidemiology study in China.A prospective study of immune and inflammation markers and risk of lung cancer among female never smokers in Shanghai.Industrial hog farming is associated with altered circulating immunological markers.Connections between pharmacoepidemiology and cancer biology: designing biologically relevant studies of cancer outcomes.Inflammatory Cytokines and Lung Cancer Risk in 3 Prospective Studies.Circulating inflammatory proteins and gallbladder cancer: Potential for risk stratification to improve prioritization for cholecystectomy in high-risk regions.
P2860
Q28394577-2A4595AB-1641-4A26-A18A-2895C7600BDDQ36181394-7A168437-9264-4603-95F8-097F775DC9B9Q37046500-A5819C84-C384-4EF1-AE7A-83665A4C7E12Q37429985-E4BD8527-BFD0-4D5B-B892-B7D8592C58F5Q37696264-3FAE9FB1-F64E-42A7-85E3-E9E7C2F8FF85Q37708960-6515B0E9-45A4-4386-8855-DD0B75C682D5Q38650328-708F71D5-89BD-4A87-AE54-5C7C8BBA5AF2Q39036378-D62ACC99-23AD-46A8-A4AD-4CDCCBB4D86FQ39507021-E856239D-402A-46C5-9884-327821F57B4EQ40044138-48584872-6ECC-4384-9414-3D23DF9106ADQ40289348-10AA37D0-1F64-420B-A973-589D34214E52Q47575301-3BD47A7B-C830-43E7-9C51-01CE292D3FE4Q47609970-2EC75677-4A7C-4C6E-A0EE-DB196BD6C2E6Q47618925-3CFDD973-AC96-458F-AE58-5060BBB3C574Q47620468-979FEE0D-CAC7-4BDB-8FC8-B37C6597E613Q49257885-FD98733C-FFE4-45E2-A380-5931262CECD6Q51247246-6EB822C6-658C-4D96-8F4F-6D99DA74346CQ52725707-75F13044-6F9A-4845-99A3-E185339C92A5
P2860
Circulating Inflammation Markers, Risk of Lung Cancer, and Utility for Risk Stratification.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Circulating Inflammation Marke ...... ility for Risk Stratification.
@en
type
label
Circulating Inflammation Marke ...... ility for Risk Stratification.
@en
prefLabel
Circulating Inflammation Marke ...... ility for Risk Stratification.
@en
P2093
P2860
P356
P1476
Circulating Inflammation Marke ...... ility for Risk Stratification.
@en
P2093
Allan Hildesheim
Anil K Chaturvedi
Eric A Engels
Hormuzd A Katki
Ligia A Pinto
Marcus Williams
Meredith S Shiels
Neil E Caporaso
Ruth M Pfeiffer
Troy J Kemp
P2860
P356
10.1093/JNCI/DJV199
P407
P577
2015-07-28T00:00:00Z